Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125494021 | 12549402 | 1 | I | 20160627 | 20160712 | 20160712 | EXP | CZ-CORDEN PHARMA LATINA S.P.A.-CZ-2016COR000185 | CORDEN | MELICHAR B, LACO J, FRIDRICHOVA P, SIMKOVIC M, PAPAJIK T, FORETOVA L.. THERAPY-RELATED MYELOID NEOPLASMS IN EPITHELIAL OVARIAN CANCER PATIENTS CARRYING BRCA1 MUTATION. REPORT OF TWO CASES.. ACTA ONCOL.. 2012;51 (1):136-138 | 0.00 | F | Y | 0.00000 | 20160712 | OT | CZ | CZ |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125494021 | 12549402 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | AUC 6 (17 CYCLES) | 19880 | |||||||||||
| 125494021 | 12549402 | 2 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | AUC 6 | 19880 | |||||||||||
| 125494021 | 12549402 | 3 | SS | PACLITAXEL. | PACLITAXEL | 1 | 175 MG/M2, EVERY 3 WEEKS (6 CYCLES) | 0 | 175 | MG/M**2 | |||||||||
| 125494021 | 12549402 | 4 | SS | PACLITAXEL. | PACLITAXEL | 1 | 175 MG/M2, (17 CYCLES) | 0 | 175 | MG/M**2 | |||||||||
| 125494021 | 12549402 | 5 | SS | PACLITAXEL. | PACLITAXEL | 1 | 175 MG/M2, UNK | 0 | 175 | MG/M**2 | |||||||||
| 125494021 | 12549402 | 6 | SS | TAMOXIFEN | TAMOXIFEN | 1 | 20 MG/DAY | U | 0 | ||||||||||
| 125494021 | 12549402 | 7 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | 1 G/M2 EVERY 2 WEEKS | 0 | |||||||||||
| 125494021 | 12549402 | 8 | SS | CISPLATIN. | CISPLATIN | 1 | 40 MG/M2, EVERY 2 WEEKS | 0 | 40 | MG/M**2 | |||||||||
| 125494021 | 12549402 | 9 | SS | DOXORUBICIN | DOXORUBICIN | 1 | 50 MG/M2, EVERY 3 WEEKS (6 CYCLES) | 0 | 50 | MG/M**2 | |||||||||
| 125494021 | 12549402 | 10 | SS | DOXORUBICIN | DOXORUBICIN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125494021 | 12549402 | 1 | Serous cystadenocarcinoma ovary |
| 125494021 | 12549402 | 3 | Serous cystadenocarcinoma ovary |
| 125494021 | 12549402 | 4 | Breast cancer |
| 125494021 | 12549402 | 6 | Serous cystadenocarcinoma ovary |
| 125494021 | 12549402 | 7 | Serous cystadenocarcinoma ovary |
| 125494021 | 12549402 | 8 | Serous cystadenocarcinoma ovary |
| 125494021 | 12549402 | 9 | Breast cancer |
| 125494021 | 12549402 | 10 | Serous cystadenocarcinoma ovary |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125494021 | 12549402 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125494021 | 12549402 | Anaemia | |
| 125494021 | 12549402 | Leukopenia | |
| 125494021 | 12549402 | Myelodysplastic syndrome | |
| 125494021 | 12549402 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125494021 | 12549402 | 2 | 200602 | 0 | ||
| 125494021 | 12549402 | 5 | 200602 | 0 | ||
| 125494021 | 12549402 | 7 | 200611 | 200703 | 0 | |
| 125494021 | 12549402 | 8 | 200611 | 200703 | 0 |